Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment.

Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,.

Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc. (ABBV), a global biopharmaceutical company, today announced an exclusive worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC®), and an expansion of their existing discovery collaboration for up to six additional targets.

Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented a poster showing preclinical data supporting HPN328 as a treatment for small cell lung cancer (SCLC) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston. The poster titled “HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer” presents a wide range of preclinical data that shows HPN328, a Tri-specific T cell Activating Construct (TriTAC®) binds to human and non-human primate DLL3, CD3ε, and albumin with similar affinities. When administered to mice bearing human SCLC xenografts and human T cells, HPN328 eradicated tumors supporting its evaluation in human cancer patients.

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,.

As of late, it has definitely been a great time to be an investor in Harpoon Therapeutics, Inc. (HARP).

Today is shaping up negative for Harpoon Therapeutics, Inc. (NASDAQ:HARP) shareholders, with the analysts delivering a...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

HPN217 is being developed under a global license and option agreement with AbbVie Inc. (ABBV) and dosing of the first patient in a clinical trial has triggered a $50 million milestone payment to Harpoon. HPN217 is Harpoon’s third product candidate to enter the clinic and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC™) platform designed to recruit a patient’s own immune cells to destroy tumors.

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,.

The poster presentation will show interim data for HPN424 from its ongoing dose escalation Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). HPN424 targets prostate-specific membrane antigen (PSMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to target and kill tumor cells.

Even if it's not a huge purchase, we think it was good to see that Georgia Erbez, the Chief Financial Officer of...

Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in.

Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVieAbstract for HPN424 interim Phase 1 data accepted.

SOUTH SAN FRANCISCO, Calif., March 05, 2020 -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,.

Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Harpoon Therapeutics, Inc. (NASDAQ:HARP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at ...

Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it has appointed Andrew R. Robbins and Joseph S. Bailes, M.D., to its Board of Directors. Dr. Bailes is a medical oncologist with substantial experience in clinical practice, legislation, public policy and advocacy, and for nearly two decades, served in various executive leadership capacities for ASCO.

Insiders invest in Fastenal, Phillips 66 Partners, Cantel Medical and Harpoon Therapeutics Continue reading...